Front. Wang, Y., Greenhalgh, T., and Wardle, J. A network analysis of the Chinese medicine Lianhua-Qingwen formula to identify its main effective components. J. Nanjing Univ. LHQW also decreased the influenza viral titers in the lungs of mice, with decreased inflammatory cytokine levels in the early stages of infection [24]. Copyright 2022 Hu, He, Gong, Liang, Zhao and Zhang. (2021). For pooled studies, there was a significantly reduced risk of adverse reactions with LHQW group compared to the conventional drug group (RR = 0.63, 95% CI = 0.580.69, p < 0.001). doi:10.1111/j.1365-2796.1990.tb00199.x, Higgins, J. P., Altman, D. G., Gtzsche, P. C., Jni, P., Moher, D., Oxman, A. D., et al. Patients with severe cases will develop acute respiratory distress syndrome and septic shock, and eventually develop multi-organ failure and death [5]. The China National Medical Products Administration agency has officially approved LHQW for the treatment of mild or ordinary COVID-19 pneumonia (Ahsan et al., 2020; Cao et al., 2020; Chan et al., 2020; Khan et al., 2020; Kupferschmidt and Cohen, 2020). Flow chart of the search and selection process. During the study, no serious adverse events were reported. Lian Hua Qing Wen capsules (LHQW) is the most effective and commonly-used clinical formula in treating respiratory infection for thousands of years in China. ex DC. Due to the low quality of the clinical research, the accuracy of this conclusion needs to be conducted to verify. Lu Z.J., Wu L.Y., Mou Y.Y., Duan H.M., Chen R.C., Xiao Y., Zheng W.J. Given the small number of documents included and the low quality, the efficacy and safety of Lianhua Qingwen Capsules shall be confirmed by more high-quality clinical studies. 2020, 3196375. doi:10.1155/2020/3196375, Yao, K. T., Liu, M. Y., Li, X., Huang, J. H., and Cai, H. B. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. Nervous system damage was described as an adverse event in 34 studies. (2020). Lianhua-qingwen Displays Antiviral and Anti-inflammatory Activity and Synergistic Effects with Oseltamivir against Influenza B Virus Infection in the Mouse Model. As a library, NLM provides access to scientific literature. COVID-19 pandemic has caused a serious threat to public health and become the greatest challenge facing the world. Chin. Recently, Yu et al. Adverse Drug Reactions to Antibiotics Observed in Two Pulmonology Divisions of Catanzaro, Italy: a Six-Year Retrospective Study. Zhong Y., Zhou J., Liang N., Liu B., Lu R., He Y., Liang C., Wu J., Zhou Y., Hu M., Zhou J. Ther. Lianhua Qingwen capsule and Lianhua Qingwen granules were approved to add "functional indications" to the originally approved indications: "In the conventional treatment of novel. sharing sensitive information, make sure youre on a federal Available at: http://www.theplantlist.org/(Accessed December 18, 2021). Lianhua Qingwen combined with conventional antiviral Western Medicine may be a useful treatment for prediabetes. In this analysis, the incidence of adverse reactions during treatment of influenza was lower in the LHQW group compared to the conventional drug group (RR = 0.74, 95% CI = 0.630.87, p < 0.001). DerSimonian, R., and Laird, N. (1986). Seven studies reporting treatment of chronic obstructive pulmonary disease were included, among which two described adverse reactions. Finally, all adverse reactions were described solely based on grouping of patients into treatment and control categories and no data were obtained according to gender stratification, which limited further analysis. Lianhua Qingwen Prescription is approved for the treatment of fever, cough, and fatigue caused by light and common type of COVID-19 . In another prospective multicenter randomized controlled trial in confirmed COVID-19 cases, Hu et al. Therefore, studies with blinded participants and personnel and blinded outcome assessments were classified as low risk of bias. In terms of incomplete outcome data and selective reporting, the majority of studies reported complete data on all symptom indicators with a low risk of attrition and reporting bias. Therefore, people have also observed that Lianhua Qingwen capsule (granule) inhibits the over-expression of human common coronavirus (HcV-229E), novel coronavirus (COVID-19) infected cells and. Study design was done by CH and BH. LHQW capsules not only had hemagglutination inhibition activity against B/Guangzhou/0215/2012 of influenza B virus, but also inhibited the over-expression of RANTES, IL-6, IL-8, IP-10, TNF-, MCP-1, macrophage inflammatory protein (MIP)-1, and interferon (IFN)- at the mRNA level and prevented a severe inflammatory response [26]. Lu Y., Yang J., Wang X., Ma Z., Li S., Liu Z., Fan X. Chen J., Wang Y.K., Gao Y., Hu L.S., Yang J.W., Wang J.R., Sun W.J., Liang Z.Q., Cao Y.M., Cao Y.B. [2] In the practice of TCM, LHQW is considered to have the effects of clearing excessive heat, removing toxins, improving lung ventilation, and discharging heat. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. [Lamiaceae; Pogostemonis Botanical drug] (85g), Rheum palmatum L. [Polygonaceae; Rhei Radix et Rhizoma] (51g), Rhodiola crenulata (Hook. [15], In the Philippines, its Food and Drug Administration approved Lianhua Qingwen on 7 August 2020 as a traditional herbal product that helps remove "heat-toxin invasion of the lungs, including symptoms such as fever, aversion to cold, muscle soreness, stuffy and runny nose". Previous studies reported that Lianhua Qingwen might have positive effects, including broad-spectrum antiviral, cough and expectorant, antipyretic and anti-inflammatory, immune-regulating, effective antibacterial and other systemic intervention functions (Liu et al., 2010; Liu 2015; Wang, et al., 2015). Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming. Further clinical trial showed that LHQW was superior to oseltamivir in improving the symptoms of influenza A virus infection by a meta-analysis of randomized, controlled trials [37]. doi:10.1111/jep.13614, Wang, Y. X., Zhang, K. Y., Huang, J. H., Han, S. L., Zhao, J. H., and Xu, Z. J. China Med. TABLE 2. There was no statistically significant difference in the incidence of abnormal white blood cells and reticuloendothelial system between the LHQW group and the conventional drug group (RR = 1.00, 95% CI = 0.382.62, p = 1.000). 160, 105101. doi:10.1016/j.phrs.2020.105101, Xiao, M., Tian, J., Zhou, Y., Xu, X., Min, X., Lv, Y., et al. Rev. World Health Organization Adverse Drug Reaction Terminology (2009). Subgroup analysis further showed the incidence of disease recurrence was lower in the LHQW group than the conventional drug group (RR = 0.33, 95% CI = 0.170.65, p = 0.001), no statistical difference was detected for secondary infection. Meanwhile, the median effective concentrations (EC50) in above-mentioned effects were 0.042, 0.031, 0.051 and 0.050mg/mL, respectively, while the prevention effect on virus adsorption was the strongest [25]. Lianhua Qingwen(Forsythiae fructus 225 mg, Lonicerae japonicae flos 225 mg, Ephedrae herba (processed w/ honey) 85 mg, Armeniacae semen amarum (stir-baked) . Medicinal Plant Names Services. [11] The pro-establishment DAB alliance was found to have distributed unregistered doses of LHQW, in breach of health regulations. Multiple clinical observations of Lianhua Qingwen combined with conventional treatment can increase the disappearance rate of major symptoms of NCP (fever, cough, fatigue) and other symptoms (chest tightness, dyspnea, and loss of appetite), and reduce the proportion of severe symptoms. In the evaluation of treating disease, the incidence of adverse reactions during treatment of influenza A (H1N1) and influenza were lower in the LHQW group compared to the conventional drug group. This review provides comprehensive evidence of LHQW as a complementary strategy for treating COVID-19. 81503129, No. 2017ZYY07). Percentage of risk of bias for all qualified studies. Clinically, Lianhua Qingwen Capsule can be used in the treatment of cold, flu-induced bronchitis, pneumonia, COPD, interstitial pneumonia and other lung inflammation. A recent clinical trial including 36 common cold with wind-heat syndrome patients demonstrated that LHQW (three times daily for four days) treatment could significantly reduce TCM symptom score, with the median time to fever relief of (45) h and the median time to fever clearance of 36h [35]. Ephedra increases heartbeat and blood pressure. The mechanisms were mainly involved the antiviral activity, and regulation of inflammation response as well as immune function. The sensitivity results are shown in Table 2. Please be informed that only the Lianhua . Role of LHQW in the treatment of COVID-19. Tradit. In the evaluation of security indexes, our meta-analysis revealed that LHQW group having a lower level of adverse reactions compared to the conventional drug group, such as respiratory system damage, skin and its appendage damage, nervous system damage, gastrointestinal system damage and other adverse reactions. Further evaluation revealed that LHQW significantly inhibited SARS-CoV-2 replication in Vero E6 cells, markedly reduced pro-inflammatory cytokines (TNF-, IL-6, CCL-2/MCP-1 and CXCL-10/IP-10) production and resulted in abnormal particle morphology of virion in cells [30]. The authors report no declarations of interest. The most common adverse reactions in our analysis were gastrointestinal system damage, skin and its appendage damage. 7 (3), 177188. Drafting of the manuscript was done by CH and BH. the contents by NLM or the National Institutes of Health. Formulae. Control. The serious attack of Coronavirus Disease 2019 (COVID-19), infected by Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (SARS-CoV-2), has quickly spread around the globe [[1], [2], [3]]. (2020). This review will elucidate the pre-clinical and clinical evidence of LHQW in lung protection and antiviral activities, and provide timely data delivery for the exploration of effective treatment strategies in the therapy of COVID-19. Inhibitory effects of three prescriptions of traditional Chinese medicine on SARS-associated coronavirus, http://kns.cnki.net/kcms/detail/11.2162.R.20200422.1429.002.html. LQ15H280003), the Clinical Research Projects of Zhejiang Medical Association (No. Publication bias data are shown in Table 2 and the Funnel plot of pooled studies presented in Figure 3. Received 2020 Jul 3; Revised 2020 Aug 9; Accepted 2020 Aug 16. China Central Television News (2020). Related tags TCM COVID-19 China A two-week clinical trial led by renowned Chinese pulmonologist Zhong Nanshan has shown that consuming the botanical TCM product Lianhua Qingwen (LH) capsules and undergoing the standard . 12 (08), 140141. A recent meta-analysis came from Zhang and Liu, (2014), focused on treatment for influenza A (H1N1) with LHQW in conjunction with oseltamivir. Vahl [Oleaceae; Forsythiae Fructus] (255g), Lonicera japonica Thunb. Since the outbreak of COVID-19, Lianhua Qingwen Capsules have been recommended by the official Chinese "Diagnosis and Treatment Protocol for COVID-19" and widely used in designated admission hospitals for COVID-19. However, the efficacy and safety of which shall be confirmed by more high-quality clinical trials. It is urgent to develop effective drugs to contain and treat COVID-19. Based Complement. Alternat Med. LHQW capsules also showed a multi-access effects on anti-human influenza A virus H3N2, including the prevention effect on virus adsorption, inhibition on virus proliferation after adsorption and direct killing of the virus [25]. Subgroup analysis additionally revealed a reduced incidence of some adverse reactions in the LHQW group compared to the conventional drug group (Rash of skin and its appendage damage, dizziness or headache owing to nervous system damage, nausea or vomiting from gastrointestinal system damage and resurgence of disease from other adverse reactions). The results remained statistically robust after different number supplement of potential studies (for hepatobiliary system damage: RR = 0.90, 95% CI = 0.60 to 1.34; for psychiatric disorders: RR = 1.00, 95% CI = 0.20 to 4.91; for gastrointestinal system damage: RR = 0.86, 95% CI = 0.76 to 0.98; for body as a whole-general disorders: RR = 0.73, 95% CI = 0.212.56). There was no statistically significant difference in the incidence of adverse reactions during treatment of common pneumonia between the LHQW group and the conventional drug group (RR = 0.99, 95% CI = 0.791.24, p = 0.927). No proven effective antiviral treatments for COVID-19 pneumonia are available at present (Ahsan et al., 2020; Cao et al., 2020; Chan et al., 2020; Khan et al., 2020; Kupferschmidt and Cohen, 2020). Yang C., Wang Y., He J., Yan W., Jiang H., Chen Q., Li L., Yang Z. Lianhua-Qingwen displays antiviral and anti-inflammatory activity and synergistic effects with oseltamivir against influenza B virus infection in the mouse model. It cannot be taken as prophylaxis or as a health supplement. Anti Covid-19 Drugs: Need for More Clinical Evidence and Global Action. 339 (7), b2535. Lianhua Qingwen Capsules has a better therapeutic effect on viral influenza, but the incidence of adverse reactions is high, and its safety must be taken seriously. BMJ. doi:10.13412/j.cnki.zyyl.2010.06.026. Tian S., Song X., Wang Y., Wang X., Mou Y., Chen Q., Zhao H., Ma K., Wu Z., Yu H., Han X., Wang H., Wang S., Ji X., Zhang Y. Chinese herbal medicine Baoyuan Jiedu decoction inhibits the accumulation of myeloid derived suppressor cells in pre-metastatic niche of lung via TGF-/CCL9 pathway. It argued that there was thus no reasonable basis for the mass distribution of the medication to healthy individuals to begin with, let alone doing so in a way that took up transportation capacity and resources that were urgently needed elsewhere. Since the adverse reactions of LHQW are relatively minor, these functional changes can be recovered. Finally, our data showed that LHQW reduces the incidence of a number of adverse reactions compared with conventional drugs. vahl (weeping forsythia) fruit 27.41 mg, Lonicera japonica Thunb. The recent network pharmacology studies showed that the effects of LHQW prescription was related to virus infection, inflammation and immunity, moreover, its main active ingredients were verified by molecular docking with angiotensin-converting enzyme 2 (ACE2), one receptor of SARS-CoV-2, so as to have a therapeutic effect on COVID-19 [[27], [28], [29]]. Inhibitorv Effect of Lianhua Oingwen Water Extract on Methicillin-Resistant staphylococcus Aureus Biofilm In Vitro. There was no statistically significant difference in the incidence of adverse reactions during treatment of hand-foot-mouth disease between the LHQW group and the conventional drug group (RR = 0.53, 95% CI = 0.221.30, p = 0.165). To clarify the in vivo effects of LHQW, Gao and colleagues recently showed that LHQW could treat influenza A virus infection in H1N1 mouse model by improving pathologic alterations and body weight loss, and reducing virus replication, lung lesions as well as inflammation [19]. 6 (01), 6364. 2015, 731765. doi:10.1155/2015/731765, Jin, L., Xu, Y., and Yuan, H. (2020). Federal government websites often end in .gov or .mil. J. Pharmacovigilance. In the evaluation of treating disease, significant reduced incidence of adverse reactions during treatment of influenza A (H1N1) and influenza were detected in the LHQW group. [3], Lianhua Qingwen was developed by Shijiazhuang Yiling Pharmaceutical in 2003 as a treatment for severe acute respiratory syndrome (SARS) following the outbreak of the disease in 2002 and was listed by the National Health Commission of China in 2004 as a treatment for influenza and other respiratory disease. The duration of sputum was shorter in the Lianhua Qingwen group than in the conventional drug group (WMD = 1.10, 95% CI = 1.50 to 0.70, < 0.001). Assoc. Duan Z.P., Jia Z.H., Zhang J., Liu S., Chen Y., Liang L.C., Zhang C.Q., Zhang Z., Sun Y., Zhang S.Q., Wang Y.Y., Wu Y.L. Yao K.T., Liu M.Y., Li X., Huang J.H., Cai H.B. Although the results obtained for influenza were consistent with our findings, the control group in this earlier study was treated with a single drug while our control groups were treated with antiviral drugs, conventional antibiotics or symptomatic therapy. In addition, LHQW treatment efficiently impaired the nuclear export of the viral RNPl [24]. Royal Botanic Gardens, Kew science (2021). Pulmonary Rale.Eighteen studies reported an effect on the duration of pulmonary rale. The site is secure. doi:10.11954/ytctyy.201608076, Chan, K. W., Wong, V. T., and Tang, S. C. W. (2020). Subgroup analysis showed a lower level of nausea or vomiting in LHQW group (RR = 0.60, 95% CI = 0.480.74, p < 0.001), no statistical difference was detected for other symptoms of gastrointestinal system damage. 52 (3), 5860. Zhang, R. X., and Liu, W. W. (2014). Results were reported as risk ratio (RR) with 95% confidence interval (CI). aimed to assess the efficacy and safety of LH combined with usual treatment vs usual treatment alone in treating mild or moderate COVID-19 by a meta-analysis of randomized controlled trials (RCTs). Alternat Med. Royal Botanic Gardens, Kew (2021). These data indicate that LHQW prescription protects against the virus attack, and it has been recommended in the treatment of COVID-19 in China [47]. While LHQW has recently been approved for marketing by CFDA, its safety is yet to be conclusively established. This work was supported by the National Natural Science Foundation of China (No. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. However, in evaluation of security index, Eggers test and funnel plot analyses disclosed the existence of publication bias with regard to hepatobiliary system damage, psychiatric disorders, gastrointestinal system damage and body as a whole-general disorders. (2013). Medicine (Baltimore). Seven of the studies showed that adverse reactions improved or healed spontaneously without any treatment, five reported that adverse reactions healed spontaneously after discontinuation of medication, eight showed that adverse reactions improved or healed with medication after meals and ten showed that adverse reactions improved or recovered after symptomatic treatment, while in the remaining eight studies, adverse reactions were not disposed or treated. Pharmacol. LYY19H280006, No. doi:10.13422/j.cnki.syfjx.20201099, Ye, C., Gao, M., Lin, W., Yu, K., Li, P., and Chen, G. (2020).
lianhua qingwen contraindication
You can post first response comment.